Cited by 2,825Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsLung Cancer Research Studies

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Open access

Forde, Patrick M., Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M., Felip, Enriqueta, Broderick, Stephen R., Brahmer, Julie R., Swanson, Scott J., Kerr, Keith, Wang, Changli, Ciuleanu, Tudor-Eliade, Saylors, Gene B., Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke-Neng, Liberman, Moishe, Vokes, Everett E., Taube, Janis M., Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y., Girard, Nicolas·2022·New England Journal of Medicine

DOI 10.1056/nejmoa2202170PMC PMC9844511

Open this paper in CoChat — free account

Abstract

BACKGROUND: Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however, data from phase 3 trials are needed to confirm these findings. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IB to IIIA resectable NSCLC to receive nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone, followed by resection. The primary end points were event-free survival and pathological complete response (0% viable tumor in resected lung and lymph nodes), both evaluated by blinded independent review. Overall survival was a key secondary end point. Safety was assessed in all treated patients. RESULTS: The median event-free survival was 31.6 months (95% confidence interval [CI], 30.2 to not reached) with nivolumab plus chemotherapy and 20.8 months (95% CI, 14.0 to 26.7) with chemotherapy alone (hazard ratio for disease progression, disease recurrence, or death, 0.63; 97.38% CI, 0.43 to 0.91; P = 0.005). The percentage of patients with a pathological complete response was 24.0% (95% CI, 18.0 to 31.0) and 2.2% (95% CI, 0.6 to 5.6), respectively (odds ratio, 13.94; 99% CI, 3.49 to 55.75; P<0.001). Results for event-free survival and pathological complete response across most subgroups favored nivolumab plus chemotherapy over chemotherapy alone. At the first prespecified interim analysis, the hazard ratio for death was 0.57 (99.67% CI, 0.30 to 1.07) and did not meet the criterion for significance. Of the patients who underwent randomization, 83.2% of those in the nivolumab-plus-chemotherapy group and 75.4% of those in the chemotherapy-alone group underwent surgery. Grade 3 or 4 treatment-related adverse events occurred in 33.5% of the patients in the nivolumab-plus-chemotherapy group and in 36.9% of those in the chemotherapy-alone group. CONCLUSIONS: In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone. The addition of nivolumab to neoadjuvant chemotherapy did not increase the incidence of adverse events or impede the feasibility of surgery. (Funded by Bristol Myers Squibb; CheckMate 816 ClinicalTrials.gov number, NCT02998528.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2202170

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,777
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citation
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L. L. C., Tsuboi, M., He, J., John, T., Grohé, C., Majem, M., Goldman, J. W., Лактионов, К. К., Kim, S., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,849
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Felip, E., Altorki, N. K., Zhou, C., Csőszi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A. V., Akopov, A. L., Martínez‐Martí, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,497
Self-citation
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Self-citation
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Self-citation
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Self-citation
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 951

Flagged first, then by citations

Show all 38 references

Sorted by citations

Items 401–500 of 1,000

Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)
Wang, Y., Deng, L., Wang, J., Zhang, T., Wang, W., Wang, X., Liu, W., Wu, Y., Lv, J., Feng, Q., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1341584 · Cited by 20
Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study
Pan, H., Chen, H., Kong, W., Ning, J., Ge, Z., Tian, Y., Zou, N., Zhu, H., Zhang, J., Tao, Y., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.03.008 · Cited by 20
Advancing non-small cell lung cancer treatment: the power of combination immunotherapies
Wu, Y., Yu, G., Jin, K., & Qian, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1349502 · Cited by 23
Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single‐cell transcriptomic analysis: Implications for distinct immunotherapy outcomes
Fang, X., Li, D., Wan, S., Hu, J., Zhang, P., Jie, D., Chen, L., Jiang, G., & Song, N. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3694 · Cited by 20
Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis
Ngo, P., Cooper, W. A., Wade, S. L., Fong, K. M., Canfell, K., Karikios, D. J., & Weber, M. F. (2025) · Scientific Reports · doi:10.1038/s41598-024-80301-9 · Cited by 19
Anatomic Lung Resection Is Associated With Improved Survival Compared With Wedge Resection for Stage IA (≤2 cm) NSCLC
Seder, C. W., Chang, S.-C., Towe, C. W., Puri, V., Blasberg, J. D., Bonnell, L., Fernández, F. G., Habib, R., & Kozower, B. D. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.03.042 · Cited by 19
Innate and adaptive immune features associated with immune-related adverse events
Khan, S., Malladi, V. S., von Itzstein, M. S., Mu-Mosley, H., Fattah, F. J., Liu, Y., Gwin, M. E., Park, J. Y., Cole, S., Bhalla, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012414 · Cited by 19
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
Remón, J., Lévy, A., Gille, R., Martel‐Lafay, I., Bortolot, M., Hendriks, L. E. L., Finn, C. F., Leighl, N. B., Reck, M., & Pérol, M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01080-4 · Cited by 19
Attention-guided framework for integrative omics and temporal dynamics in predicting major pathological response in neoadjuvant immunochemotherapy for NSCLC
Gan, X., He, J., Zhang, W., Chen, W., Liu, S., Li, W., Duan, X., Lv, L., Liang, Y., Cao, Q., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012526 · Cited by 20
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Provencio, M., Awad, M. M., Spicer, J. D., Janssens, A., Moiseyenko, F. V., Gao, Y., Watanabe, Y., Alexandru, A., Guisier, F., Frost, N., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01104-z · Cited by 19
Self-citation
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
Goss, G. D., Darling, G. E., Westeel, V., Nakagawa, K., Massutí, B., Perrone, F., McLachlan, S., Kang, J. H., Wu, Y.-L., Dingemans, A. C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01828 · Cited by 19
Self-citation
Minimal residual disease in solid tumors: Clinical applications and future directions
Abdo, T., Alhalabi, A., Yaghi, S., Aloran, M., Li, Y., Herrán, M., Tfayli, R., Samuel, T. A., & Nahleh, Z. A. (2026) · Cancer · doi:10.1002/cncr.70286 · Cited by 19
Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
Remón, J., Lévy, A., Singh, P., Hendriks, L. E. L., Aldea, M. D., & Arrieta, O. G. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221113268 · Cited by 19
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada
Kuruvilla, M. S., Liu, G., Syed, I. A., Gwadry-Sridhar, F. H., Sheffield, B. S., Sachdeva, R., Pencz, A., Zhan, L. J., Hueniken, K., Patel, D., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.08.023 · Cited by 19
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
Signorelli, D., Ghidotti, P., Proto, C., Brambilla, M., Toma, A. D., Ferrara, R., Galli, G., Ganzinelli, M., Russo, G. L., Prelaj, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.987639 · Cited by 19
Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
Cai, W., Jing, M., Gu, Y., Bei, T., Zhao, X., Chen, S., Wen, J., Gao, J., Wu, C., & Xue, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984666 · Cited by 19
Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
Dai, F., Wu, X., Wang, X., Li, K., Wang, Y., Shen, C., Zhou, J., Niu, H., Deng, B., Tan, Q., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022123 · Cited by 19
Feasibility of shape-sensing robotic-assisted bronchoscopy for biomarker identification in patients with thoracic malignancies
Connolly, J. G., Kalchiem‐Dekel, O., Tan, K. S., Dycoco, J., Chawla, M. K., Rocco, G., Park, B. J., Lee, R. P., Beattie, J., Solomon, S. B., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.10.059 · Cited by 19
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Liveringhouse, C. L., Latifi, K., Asous, A. G., Lam, N. B., Rosenberg, S. A., Dilling, T. J., Macmillan, G., Chiappori, A., Haura, E. B., Creelan, B., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.01.006 · Cited by 19
A View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0776 · Cited by 21
Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy
Sarkar, J., Gomez, E. C., Oba, T., Chen, H., Dy, G. K., Segal, B. H., Ernstoff, M. S., & Ito, F. (2023) · World Journal of Oncology · doi:10.14740/wjon1587 · Cited by 19
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Singh, N., Daly, M. E., Ismaila, N., Panel, F. T. M. O. S. I. N. G. E., Daly, M. E., Singh, N., Antonoff, M. B., Arenberg, D. A., Bradley, J. D., David, E. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01261 · Cited by 19
Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial Treatment
Dickhoff, C., Heineman, D. J., Bahce, I., & Senan, S. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.06.002 · Cited by 19
Cisplatin Dependent Secretion of Immunomodulatory High Mobility Group Box 1 (HMGB1) Protein from Lung Cancer Cells
Gillespie, K. P., Pirnie, R., Mesaros, C., & Blair, I. A. (2023) · Biomolecules · doi:10.3390/biom13091335 · Cited by 19
Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
Liu, J., Liu, D., Hu, G., Wang, J., Chen, D., Song, C., Cai, Y., Zhai, C., & Xu, W. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03137-9 · Cited by 19
Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study
Qu, W., Chen, C., Cai, C., Gong, M., Luo, Q., Song, Y., Yang, M., & Shi, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1327779 · Cited by 23
Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer
Myers, S. P., Sevilimedu, V., Jones, V. M., Abuhadra, N. K., Montagna, G., Plitas, G., Morrow, M., & Downs‐Canner, S. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15359-w · Cited by 19
Stage III NSCLC treatment options: too many choices
Asmara, O. D., Hardavella, G. F., Ramella, S., Petersen, R. H., Tietzova, I., Boerma, E. C., Tenda, E. D., Bouterfas, A., Heuvelmans, M. A., & van Geffen, W. H. (2024) · Breathe · doi:10.1183/20734735.0047-2024 · Cited by 19
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)
Duan, H., Shao, C., Luo, Z., Wang, T., Tong, L., Liu, H., Yao, X., Lei, J., Zhao, J., Gao, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01992-0 · Cited by 20
Dynamics and Half-Life of Cell-Free DNA After Exercise: Insights from a Fragment Size-Specific Measurement Approach
Yamamoto, R., Asano, H., Ryo, T., Saito, Y., Hosokawa, A., Watari, H., & Umazume, T. (2025) · Diagnostics · doi:10.3390/diagnostics15010109 · Cited by 19
Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results
Ziogas, D. C., Theocharopoulos, C., Aravantinou-Fatorou, K., Boukouris, A. E., Stefanou, D. T., Anastasopoulou, A. N., Lialios, P., Lyrarakis, G., & Gogas, H. J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104635 · Cited by 21
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy
Phillips, W. J., Camidge, D. R., & Wheatley‐Price, P. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.10.010 · Cited by 20
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care
Topalian, S. L., & Pardoll, D. M. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010833 · Cited by 19
Surgery challenges and postoperative complications of lung cancer after neoadjuvant immunotherapy
Bai, G., Chen, X., Yue, P., Ji, Y., Bie, F., Liu, Y., Yang, Z., & Gao, S. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15297 · Cited by 18
Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection
Resio, B. J., Tan, K. S., Skovgard, M. S., Dycoco, J., Adusumilli, P. S., Bains, M. S., Bott, M. J., Downey, R. J., Gray, K., Huang, J. G., et al. (2024) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2024.09.009 · Cited by 18
Combinational CAR T-cell therapy for solid tumors: Requisites, rationales, and trials
Misawa, K., Bhat, H., Adusumilli, P. S., & Hou, Z. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108763 · Cited by 20
Cancer theragnostics: closing the loop for advanced personalized cancer treatment through the platform integration of therapeutics and diagnostics
Sergeeva, O. V., Luo, L., & Guiseppi‐Elie, A. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1499474 · Cited by 18
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
Kim, J., Park, S., Ku, B. M., & Ahn, M. (2025) · Cancer · doi:10.1002/cncr.35778 · Cited by 20
Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis
Zhang, Z., Lin, Y., & Chen, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569864 · Cited by 18
Clinical Outcomes of Perioperative Immunotherapy in Resectable Non–Small Cell Lung Cancer
Desai, A. P., Schwed, K., Kalesinskas, L., Yuan, Q., Bryan, J., Keane, C., Fidyk, E., Castellanos, E. H., Cohen, A. B., Harrison, K., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17953 · Cited by 18
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses
Rossi, G., Barcellini, L., Tagliamento, M., Tanda, E. T., Garassino, M. C., Blondeaux, E., Delucchi, V., Spagnolo, F., Mastro, L. D., & Genova, C. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105759 · Cited by 18
ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma
Liu, Z., Wang, G., Yang, Y., Su, Y., Zhang, H., Liu, J., Cui, P., Fan, X., Yang, J., Zhang, Z., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102334 · Cited by 18
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
Dingemans, A. C., Opitz, I., Brunelli, A., Remón, J., Hendriks, L. E. L., Edwards, J., Finn, C. F., Reguart, N., Smit, E. F., Lévy, A., et al. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00051-2 · Cited by 18
Senescence in cancer: Hallmarks, paradoxes, and therapeutic promise
Hinterleitner, C., Goldberg, H. V., McHugh, D., Barthet, V. J. A., Filliol, A. A., & Lowe, S. W. (2026) · Cell · doi:10.1016/j.cell.2026.03.005 · Cited by 20
Cell-by-Cell: Unlocking Lung Cancer Pathogenesis
Sinjab, A. F., Rahal, Z., & Kadara, H. N. (2022) · Cancers · doi:10.3390/cancers14143424 · Cited by 19
Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
Leal, T. A. B., & Ramalingam, S. S. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100691 · Cited by 18
Safety and feasibility of minimally invasive lobectomy after neoadjuvant immunotherapy for non–small cell lung cancer
Mathey-Andrews, C. A., McCarthy, M. L., Potter, A. L., Beqari, J., Wightman, S. C., Liou, D. Z., Raman, V., & Yang, C. J. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.12.006 · Cited by 18
Neoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer—Is a New Era Coming?
Zhang, B., Zhong, H., & Han, B. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.6898 · Cited by 18
Personalized treatment for patients with lung cancer
Schüler, M., Bölükbas, S., Darwiche, K., Theegarten, D., Herrmann, K., & Stuschke, M. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0012 · Cited by 20
Expert consensus on treatment for stage III non‐small cell lung cancer
Wu, Y.-L. L. C., Lü, S., Zhou, Q., Zhang, L., Cheng, Y., Wang, J., Wang, B., Hu, C., Lin, L., Zhong, W., et al. (2023) · Medicine Advances · doi:10.1002/med4.7 · Cited by 18
Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study
Yin, C., Zou, G., He, Y., Li, J., Yan, H., Su, Z., Cao, X., & Li, X. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-387 · Cited by 18
Immunotherapy for early-stage non-small cell lung cancer: A system review
Gao, J., Zhang, C., Wei, Z., & Ye, X. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_723_23 · Cited by 18
Modern Stereotactic Radiotherapy for Brain Metastases from Lung Cancer: Current Trends and Future Perspectives Based on Integrated Translational Approaches
Levis, M., Gastino, A., Giorgi, G. D., Mantovani, C., Bironzo, P., Mangherini, L., Ricci, A. A., Ricardi, U., Cassoni, P., & Bertero, L. (2023) · Cancers · doi:10.3390/cancers15184622 · Cited by 19
Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non‐small cell lung cancer: A retrospective study
Xu, F., Zhu, H., Xiong, D., Wang, K., Dong, Y., Li, L., & Yuan, S. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15175 · Cited by 18
Diagnosis, treatment, and prognosis of stage IB non-small cell lung cancer with visceral pleural invasion
Ruan, Z., Zhuo, X., & Xu, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1310471 · Cited by 18
Efficacy and safety of camrelizumab combined with oxaliplatin and S‐1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II , single‐arm study
Zhong, W.-J., Lin, J., Wu, C., Wang, J., Chen, J., Zheng, H., & Ye, K. (2024) · Cancer Medicine · doi:10.1002/cam4.7006 · Cited by 18
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?
Spagnolo, C. C., Pepe, F., Ciappina, G., Nucera, F., Ruggeri, P., Squeri, A., Speranza, D., Silvestris, N., Malapelle, U., & Santarpía, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104332 · Cited by 18
Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study
Guan, S., Jifeng, S., Wang, Y., Han, S., Chen, C., Yue, D., Huang, Y., Ren, K., Wang, J., Wang, J., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03696-4 · Cited by 18
Moving Immunotherapy Into the Treatment of Resectable Non–Small Cell Lung Cancer
Chaft, J. E., Dziadziuszko, R., & Goulart, B. H. L. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432500 · Cited by 18
The role of immunotherapy in early-stage and metastatic NSCLC
Lieber, A., Makai, A., Orosz, Z. Z., Kardos, T., Isaac, S. J., Tornyi, I., & Bittner, N. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611713 · Cited by 18
Stage I and II nonsmall cell lung cancer treatment options
Hardavella, G. F., Magouliotis, D. E., Chalela, R., Januszewski, A. P., Dennstädt, F., Putora, P. M., So, A., & Bhowmik, A. (2024) · Breathe · doi:10.1183/20734735.0219-2023 · Cited by 18
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial
Yi, C., Bian, D., Wang, J., Hu, S., Sun, L., Yan, Y., Wang, S., Shen, Z., Yu, H., Yang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57184-z · Cited by 18
Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review
Aguiar-Ibáñez, R., Mbous, Y. P. V., Sharma, S., & Chawla, E. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1546447 · Cited by 17
Lymph node dissection in lung cancer surgery: a comparison between robot-assisted vs. video-assisted thoracoscopic approach
Hurley, P. D., Fabbri, G., Berjaoui, N., Patel, A. J., Lampridis, S., Routledge, T., & Billè, A. (2024) · Frontiers in Surgery · doi:10.3389/fsurg.2024.1395884 · Cited by 17
Adjuvant immunotherapy does not improve survival in non–small cell lung cancer with major/complete pathologic response after induction immunotherapy
Zhao, Z.-R., Yan, W., Yu, X., Zhang, J., Fang, Y., Ma, K., Luo, Q., Long, H., Chen, K., & Jiang, L. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.11.028 · Cited by 17
Self-citation
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
Schmid, D., Sobottka, B., Manzo, M., Trüb, M., Leonards, K., Herzig, P., Oyewole, O. R.-A., Jermann, P. M., Hayoz, S., Prince, S. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63696-5 · Cited by 17
Toward a cure for lung cancer: important advances in operable non-small cell lung cancer
Liu, S. M., Jie, G., & Wu, Y.-L. L. C. (2022) · 中国科学通报：英文版 · doi:10.1016/j.scib.2022.06.008 · Cited by 17
A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
Liu, W. Y., Zhang, T., Zhang, Q., Li, L., & Xu, C. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02292-5 · Cited by 17
Perioperative Therapy for Resectable Non–Small-Cell Lung Cancer: Weighing Options for the Present and Future
Uprety, D., & West, H. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00014 · Cited by 18
Sub-Lobar Resection: The New Standard of Care for Early-Stage Lung Cancer
Lee, B. E., & Altorki, N. K. (2023) · Cancers · doi:10.3390/cancers15112914 · Cited by 17
Current and emerging applications of liquid biopsy in pan-cancer
Wang, W., He, Y., Yang, F., & Chen, K. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101720 · Cited by 17
Self-citation
Deep Learning for Predicting Effect of Neoadjuvant Therapies in Non–Small Cell Lung Carcinomas With Histologic Images
Terada, K., Yoshizawa, A., Liu, X., Ito, H., Hamaji, M., Menju, T., Date, H., Bise, R., & Haga, H. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100302 · Cited by 18
Self-citation
Granzyme B (GZMB)-Positive Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma: Significance as a Prognostic Factor and Association with Immunosuppressive Proteins
Kinoshita, F., Takada, K., Wakasu, S., Saito, S., Hashinokuchi, A., Matsudo, K., Nagano, T., Akamine, T., Kohno, M., Takenaka, T., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14085-z · Cited by 17
Recent Advances in Perioperative Immunotherapies in Lung Cancer
Fukuda, S., Suda, K., Hamada, A., & Tsutani, Y. (2023) · Biomolecules · doi:10.3390/biom13091377 · Cited by 18
Drug resistance mechanism and reversal strategy in lung cancer immunotherapy
Xu, Y., Liu, Y., Ge, Y., Li, H., Zhang, Y., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1230824 · Cited by 17
PD-1/PD-L1 Inhibitors plus Chemotherapy Versus Chemotherapy Alone for Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Pasqualotto, E., de Moraes, F. C. A., Pedrotti, M., Souza, M. E. C., Rodrigues, A. L. S. D. O., Ferreira, R. O. M., Lopes, L. M., de Almeida, A. M., Fernandes, M. R., & dos Santos, N. P. C. (2023) · Cancers · doi:10.3390/cancers15215143 · Cited by 17
Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816
Wang, C., Chen, K.-N., Chen, Q., Wu, L., Wang, Q., Li, X., Ying, K., Wang, W., Zhao, J., Liu, L., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102040 · Cited by 19
Self-citation
Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review
Bai, Y., Yang, W., Käsmann, L., Sorich, M. J., Tao, H., & Hu, Y. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-144 · Cited by 17
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
Verma, S., Breadner, D. A., Mittal, A., Palma, D. A., Nayak, R., Raphael, J., & Vincent, M. D. (2024) · Cancers · doi:10.3390/cancers16071302 · Cited by 17
Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
Hu, M., Zhong, C., Wang, J., Chen, J., & Zhou, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399975 · Cited by 17
Predicting therapeutic response to neoadjuvant immunotherapy based on an integration model in resectable stage IIIA (N2) non–small cell lung cancer
Xu, L., Si, H., Zhuang, F., Li, C., Zhang, L., Zhao, Y., Chen, T., Dong, Y., Wang, T., Hou, L., et al. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.05.006 · Cited by 17
Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study
Guo, Y., Xu, X., Wang, T., Liu, Y., Gu, D., Fang, Y., Wang, Q., Shi, H., wu, D., Zhang, Z., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112558 · Cited by 18
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Monette, A., Warren, S., Barrett, J. C., Garnett‐Benson, C., Schalper, K. A., Taube, J. M., Topp, B. G., & Snyder, A. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009427 · Cited by 17
Self-citation
The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer
Akdoğan, O., Öğüt, B., Sütçüoğlu, O., Sert, A., Gürler, F., Akyürek, N., Özdemir, N., Özet, A., & Yazıcı, O. (2024) · BMC Cancer · doi:10.1186/s12885-024-12727-3 · Cited by 17
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Lavaud, P., Bortolot, M., Zullo, L., O’Reilly, D., Naidoo, J., Mountzios, G., Mercier, O. M., Hendriks, L. E. L., & Remón, J. (2024) · Cancers · doi:10.3390/cancers16162779 · Cited by 18
The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer
Guo, R., Yan, W., Wang, F., Su, H., Meng, X., Xie, Q. M., Zhao, W., Yang, Z., & Li, N. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00772-x · Cited by 17
Oligometastatic non‐small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome
Wiesweg, M., Küter, C., Schnorbach, J., Keyl, J., Metzenmacher, M., Cvetkovic, J., Saalfeld, F. C., Glanemann, F., Eberhardt, W., Öezkan, F., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35199 · Cited by 17
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS- Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Rosner, S., Connor, S. C., Sanber, K. S., ZAHURAK, M. L., Zhang, T., Gurumurthy, I., Zeng, Z., Presson, B., Singh, D., Rayes, R. F., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2983 · Cited by 18
Self-citation
Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study
Zhai, W., Zhang, C., Duan, F., Xie, J., Dai, S., Lin, Y., Yan, Q., Rao, B.-Y., Li, L., Zhou, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1422717 · Cited by 16
Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Resectable Non–small Cell Lung Cancer Treated With Neoadjuvant Immunotherapy Plus Chemotherapy
Cheng, Y., Jiang, Z.-P., Chen, X., Lu, K.-Y., Liu, Z., & Shao, D. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005863 · Cited by 16
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit
Pauken, K. E., Alhalabi, O., Goswami, S., & Sharma, P. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.005 · Cited by 18
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
Spigel, D. R., Westeel, V., Anderson, I. C., Greillier, L., Guisier, F., Bylicki, O., Badin, F. B., Rousseau-Bussac, G., Deldycke, C., Griesinger, F., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00213-9 · Cited by 16
Multichannel deep learning prediction of major pathological response after neoadjuvant immunochemotherapy in lung cancer: a multicenter diagnostic study
Geng, Z., Li, K., Mei, P., Gong, Z., Yan, R., Huang, Y., Zhang, C., Zhao, B., Lu, M., Yang, R., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002821 · Cited by 16
Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer
Laengle, J., Kuehrer, I., Kulu, A., Kabiljo, J., Ammon, D., Zirnbauer, R., Stift, A., Herbst, F., Dauser, B., Monschein, M., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.27769 · Cited by 16
Tumor-derived exosomal tsRNA 3′tiRNA-AlaCGC in promoting fibroblast senescence and Galectin-9 secretion to induce immune tolerance in lung adenocarcinoma
Guangyin, Z., Zhang, Y., Zhang, H., Guo, Y., Xu, C., Ge, D., & Gu, J. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02695-3 · Cited by 17
Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer
Provencio, M., Serna-Blasco, R., Nadal, E., González-Larriba, J. L., Martínez‐Martí, A., Bernabé, R., Bosch‐Barrera, J., Calvo, V., Molla, A. I., Reguart, N., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2958 · Cited by 16
Self-citation
Prognostic score and sex-specific nomograms to predict survival in resectable lung cancer: a French nationwide study from the Epithor cohort database
Alifano, M., Daffré, E., Brouchet, L., Falcoz, P., Pimpec‐Barthes, F. L., Pagès, P., Thomas, P. A., Dahan, M., & Porcher, R. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100566 · Cited by 16
Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer
Alì, G., Poma, A. M., Stefano, I. D., Zirafa, C. C., Lenzini, A., Martinelli, G., Romano, G., Chella, A., Baldini, E., Melfi, F. M. A., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1115156 · Cited by 16
Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions
Schenk, E. L. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-883 · Cited by 18
NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know
Mitchell, C. L., Zhang, A. L., Bruno, D. S., & Almeida, F. A. (2023) · Diagnostics · doi:10.3390/diagnostics13061117 · Cited by 16

Authors: Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., Kerr, K., Wang, C., Ciuleanu, T.-E., Saylors, G. B., Tanaka, F., Ito, H., Chen, K.-N., Liberman, M., Vokes, E. E., Taube, J. M., Dorange, C., Cai, J., Fiore, J., Jarkowski, A., Balli, D., Sausen, M., Pandya, D., Calvet, C. Y., & Girard, N.
Affiliations: Johns Hopkins University (US)
From the Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore (P.M.F., S.R.B., J.R.B., J.M.T.); McGill University Health Center (J.S.), and Centre Hospitalier de l’Université de Montréal (M.L.) — both in Montreal; Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai (S.L.), Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin (C.W.), and Peking University School of Oncology, Beijing Cancer Hospital, Beijing (K.-N.C.) — all in China; Hospital Universitario Puerta de Hierro, Madrid (M.P.); Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama (T.M.), the University of Occupational and Environmental Health, Kitakyushu (F.T.), and Kanagawa Cancer Center, Yokohama (H.I.) — all in Japan; Dana–Farber Cancer Institute, Boston (M.M.A., S.J.S.); Vall d’Hebron Institute of Oncology, Barcelona (E.F.); Aberdeen Royal Infirmary, Aberdeen, United Kingdom (K.K.); Institutul Oncologic Prof. Dr....
ORCID: Forde, Patrick M.
Felip, Enriqueta
Calvet, Christophe Y.
Girard, Nicolas
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2022-05-26
Volume: 386
Issue: 21
Pages: 1973-1985
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2202170
PMC: PMC9844511
OpenAlex: W4223502512
Cited by: 2,825
References: 38
Citations by year: 2026: 583 · 2025: 683 · 2024: 724 · 2023: 624 · 2022: 209
FWCI: 361.74
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Bristol-Myers Squibb (N/A)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: nivolumab, neoadjuvant therapy, non-small cell lung cancer, resectable lung cancer, platinum-based chemotherapy, immune checkpoint inhibitors, event-free survival, pathological complete response, overall survival, treatment-related adverse events
MeSH terms: Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Recurrence, Local, Platinum Compounds, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks